Shares of Intra-Cellular Therapies (ITCI) rallied 14.9% on Friday after the company announced that it has entered into a settlement agreement with Sandoz (SDZNY) regarding the Caplyta (lumateperone) patent litigation.The settlement agreement resolves the patent litigation brought by Intra-Cellular on Sandoz for submitting an abbreviated new drug application to the FDA seeking marketing approval for a generic version of Caplyta in the United States before applicable patents expire. The litigation is currentl ...